Abstract：
BACKGROUND: Capsular contracture (CC) remains a very common complication and the main cause of reoperation following a mammary implant surgery. Leukotrienes play an important role in the inflammatory cascade linked to the development of the periprosthetic capsule. The aim of this paper is to evaluate the incidence of recurrence of capsular contracture in female patients who underwent a secondary mammary augmentation due to this etiology, with and without treatment with leukotriene inhibitors during postoperative care.
METHODS: Sixty-four women submitted to a secondary mammary augmentation due to CC were evaluated retrospectively. Out of these patients, 20 (31%) were treated with Montelukast for 3 months. The remaining 44 (69%) did not receive antileukotriene. The presence of capsular contracture was measured using the Baker classification and magnetic resonance imaging a year after postoperative care. The median follow-up period was 15 months.
RESULTS: The patients receiving Montelukast (n = 20) presented a 15% CC rate (n = 1). The women that did not receive antileukotriene therapy (n = 44) presented a 16% CC rate (n = 7).
CONCLUSIONS: The results of our study show that treatment with Montelukast for 3 months after the operation is associated with lower rates of capsular contracture when compared to patients that did not receive the treatment.
METHODS: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
METHODS: Sixty-four women submitted to a secondary mammary augmentation due to CC were evaluated retrospectively. Out of these patients, 20 (31%) were treated with Montelukast for 3 months. The remaining 44 (69%) did not receive antileukotriene. The presence of capsular contracture was measured using the Baker classification and magnetic resonance imaging a year after postoperative care. The median follow-up period was 15 months.
RESULTS: The patients receiving Montelukast (n = 20) presented a 15% CC rate (n = 1). The women that did not receive antileukotriene therapy (n = 44) presented a 16% CC rate (n = 7).
CONCLUSIONS: The results of our study show that treatment with Montelukast for 3 months after the operation is associated with lower rates of capsular contracture when compared to patients that did not receive the treatment.
METHODS: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
摘要：
背景：囊膜挛缩症（CC）仍然是非常常见的并发症，也是乳房植入手术后再次手术的主要原因。白三烯在与假体周围囊发育相关的炎症级联中起重要作用。本文的目的是评估由于这种病因而进行二次乳腺扩张的女性患者的包膜挛缩复发率。术后护理期间有或没有白三烯抑制剂治疗。
方法：回顾性评估64例因CC而接受二次乳房增大术的女性。在这些病人中，20例(31%)用孟鲁司特治疗3个月。其余44人（69％）没有接受抗白三烯。术后一年后，使用Baker分类和磁共振成像测量包膜挛缩的存在。中位随访期为15个月。
结果：接受孟鲁司特（n=20）的患者的CC率为15％（n=1）。未接受抗白三烯治疗的妇女（n=44）的CC率为16％（n=7）。
结论：我们的研究结果表明，与未接受治疗的患者相比，术后3个月使用孟鲁司特治疗的包膜挛缩率较低。
方法：本期刊要求作者为每篇文章分配一定程度的证据。对于这些循证医学评级的完整描述，请参阅目录或在线作者说明www。springer.com/00266.
方法：回顾性评估64例因CC而接受二次乳房增大术的女性。在这些病人中，20例(31%)用孟鲁司特治疗3个月。其余44人（69％）没有接受抗白三烯。术后一年后，使用Baker分类和磁共振成像测量包膜挛缩的存在。中位随访期为15个月。
结果：接受孟鲁司特（n=20）的患者的CC率为15％（n=1）。未接受抗白三烯治疗的妇女（n=44）的CC率为16％（n=7）。
结论：我们的研究结果表明，与未接受治疗的患者相比，术后3个月使用孟鲁司特治疗的包膜挛缩率较低。
方法：本期刊要求作者为每篇文章分配一定程度的证据。对于这些循证医学评级的完整描述，请参阅目录或在线作者说明www。springer.com/00266.
